VIDEO: Framing ASCO findings from a patient advocate perspective
In this video, Upal Basu Roy, PhD, MPH, vice president of research at LUNGevity Foundation, spoke with Healio about three important presentations in non-small cell cancer from this year’s ASCO annual meeting.
Roy contextualized his perspective as both a scientist and a patient advocate, highlighting data from the ADAURA trial, the CITYSCAPE trial and a phase 1b multicenter study exploring the efficacy of trastuzumab deruxtecan plus pembrolizumab against HER2 mutations in patients with non-small cell lung cancer (NSCLC).
He also discussed recent FDA approvals for the treatment of advanced-stage NSCLC, including capmatinib (Tabrecta; Novartis), ipilimumab (Yervoy; Bristol-Myers Squibb) plus nivolumab (Opdivo; Bristol-Myers Squibb), and ipilimumab and nivolumab plus chemotherapy.
“As a scientist, this makes me very, very excited because this tell me we have more options for our patients,” Roy said.
But he also wanted to emphasize the perspective of patients.
“When these new drugs come into the market, I feel that patient preference is of paramount importance,” Roy explained.
References:
- Borghaei H, et al. Abstract TPS1100. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
- Herbst RS, et al. Abstract LBA5. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
- Rodriguez-Abreu D, et al. Abstract 9503. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Collapse
Healio Interview